Shopping Cart
- Remove All
Your shopping cart is currently empty
Linaprazan (AZD0865) inhibits gastric H+,K+-ATPase through K+-competitive binding, with an IC50 of 1.0 μM.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $43 | In Stock | |
| 10 mg | $73 | In Stock | |
| 25 mg | $148 | In Stock | |
| 50 mg | $223 | In Stock | |
| 100 mg | $375 | In Stock |
| Description | Linaprazan (AZD0865) inhibits gastric H+,K+-ATPase through K+-competitive binding, with an IC50 of 1.0 μM. |
| Targets&IC50 | K+ competitive binding:1.0 μM |
| In vitro | Linaprazan (AZD0865) can inhibit the final step in acid secretion. Linaprazanreduced porcine renal Na+, K+-ATPase activity by 9 ± 2% [1]. |
| In vivo | The reference for animal administration is 0.5-1.0 mg/kg. The greater degree of acid suppression with the 75-mg dose of Linaprazan would translate to a healing rate of 89% at 4 weeks [2]. |
| Synonyms | AZD0865 |
| Molecular Weight | 366.46 |
| Formula | C21H26N4O2 |
| Cas No. | 248919-64-4 |
| Smiles | Cc1nc2c(NCc3c(C)cccc3C)cc(cn2c1C)C(=O)NCCO |
| Relative Density. | 1.21 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 3.67 mg/mL (10 mM), Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.